News and Press Releases
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV 10 October 2025 -- Cairo, Egypt; Berlin, Germany; and New York, New York -- IAVI,...
Category: Biotechnology, Drug Delivery, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 10, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
6 March 2025 -- Berlin, Germany -- ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded
February 04, 2025 – Berlin, Germany – Biotech Newswire / -- ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded...
Category: Biotechnology
Posted: February 5, 2025
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval 22 August 2024 -- Massachusetts, US -- Moderna, Inc today...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 22, 2024
Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease
12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024
SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases
12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024
ModeX Therapeutics Leverages ProBioGen’s Expertise for Accelerated COVID-19 Antibody Development
29 May 2024 -- Berlin, Germany -- ProBioGen, a leading contract development and manufacturing organisation (CDMO), known for its innovative solutions in cell engineering and bioprocessing excellence, announces a pivotal...
Category: BioManufacturing, Biotechnology, Pharmaceutical
Posted: May 29, 2024
ProBioGen Announces Change in Management
30 April 2024 -- Berlin, Germany -- ProBioGen AG, a premier contract development and manufacturing organisation (CDMO) and technology provider with extensive expertise in cell line engineering, process development and GMP...
Category: BioManufacturing, Other
Posted: April 30, 2024
Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children
Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...
Category: Pharmaceutical
Posted: April 9, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC for Ground-breaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
13 March 2024 -- Berlin, Germany -- ProBioGen, a leading CDMO of innovative solutions and services for biopharmaceutical development, is pleased to announce the execution of services and license agreements...
Category: Biotechnology
Posted: March 13, 2024
New partnership aims to advance vaccine against MERS coronavirus
CEPI to invest up to $47m to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500 VTP-500 project with Barinthus Bio and University of Oxford, UK, uses...
Category: Clinical Trials
Posted: January 2, 2024
AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...
Category: Clinical Trials
Posted: October 12, 2023
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...
Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...
Category: Clinical Trials
Posted: September 20, 2023
MODERNA RECEIVES US FDA APPROVAL FOR UPDATED COVID-19 VACCINE
Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86 Updated vaccine to be available in pharmacies and care settings across the US in the...
Category: Clinical Trials
Posted: September 12, 2023
